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Rhabdoid tumors (RTs) of the brain (atypical teratoid/rhabdoid tumor; AT/RT) and
extracranial sites (most often the kidney; RTK) are malignant tumors predominantly
occurring in children, frequently those with SMARCB1 germline alterations. Here we
present data from seven RTs from three pediatric patients who all had multi-organ
involvement. The tumors were analyzed using a multimodal molecular approach, which
included exome sequencing of tumor and germline comparator and RNA sequencing and
DNA array-based methylation proﬁling of tumors. SMARCB1 germline alterations were
identiﬁed in all patients and in all tumors. We observed a second hit in SMARCB1 via chr22
loss of heterozygosity. By methylation proﬁling, all tumors were classiﬁed as rhabdoid
tumors with a corresponding subclassiﬁcation within the MYC, TYR, or SHH AT/RT
subgroups. Using RNA-seq gene expression clustering, we recapitulated the
classiﬁcation of known AT/RT subgroups. Synchronous brain and kidney tumors from
the same patient showed different patterns of either copy number variants, singlenucleotide variants, and/or genome-wide DNA methylation, suggestive of non-clonal
origin. Furthermore, we demonstrated that a lung and abdominal metastasis from two
patients shared overlapping molecular features with the patient’s primary kidney tumor,
indicating the likely origin of the metastasis. In addition to the SMARCB1 events, we
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identiﬁed other whole-chromosome events and single-nucleotide variants in tumors, but
none were found to be prognostic, diagnostic, or offer therapeutic potential for rhabdoid
tumors. While our ﬁndings are of biological interest, there may also be clinical value in
comprehensive molecular proﬁling in patients with multiple rhabdoid tumors, particularly
given the potential prognostic and therapeutic implications for different rhabdoid tumor
subgroups demonstrated in recent clinical trials and other large cohort studies.
Keywords: atypical teratoid/rhabdoid tumor (AT/RT), malignant rhabdoid tumor (MRT), SMARCB1, next-generation
sequencing, DNA methylation array

of tumors or in longitudinal samples from patients who experience
metastasis of their primary tumor.
Here we present a case series of three pediatric patients
diagnosed and treated for AT/RT and/or RTK. We analyzed
multiple different tumors from each patient, totaling seven
tumor samples, including primary tumors and metastases. Each
tumor was comprehensively analyzed using a multimodal
molecular characterization approach that included exome
sequencing for detection of germline and somatic variants and
copy number alterations, whole transcriptome sequencing (RNAseq), DNA array-based methylation analyses, and clonality
analysis. Our approach uncovered a consistent biallelic
inactivation of SMARCB1 as expected but revealed molecular
heterogeneity among tumors from the same individual.

INTRODUCTION
Rhabdoid tumors (RT) are rare, malignant tumors diagnosed most
often in early childhood. RTs are classiﬁed according to their
anatomical location and most often arise in the brain (atypical
teratoid/rhabdoid tumor; AT/RT) and/or extracranially, usually in
the kidney (RTK) and sometimes in other soft tissues like muscles
(1, 2). In the United States, AT/RT represents 10% of primary brain
and central nervous system (CNS) tumors diagnosed in individuals
less than 1 year of age (1). RTKs account for 18% of all renal tumors
diagnosed in infants (2). Because of the rarity and aggressiveness of
RTs and given the young age of many patients, there is no deﬁned
standard of care, and RTs remain one of the most lethal childhood
tumors with overall survival rates <50% (3–5).
Almost all cases of RT, regardless of anatomical site, are
molecularly characterized by the biallelic alteration of SMARCB1,
leading to complete inactivation of the gene and, more rarely,
inactivation of SMARCA4 in a germline or somatic setting (6–8).
SMARCB1, also called INI1/BAF47/SNF5, is an established tumor
suppressor at 22q11.2 that encodes a subunit protein of the SWI/
SNF chromatin remodeling complex (9). In approximately 35% of
individuals diagnosed with an AT/RT or RTK, one of the
SMARCB1 alterations is present in the germline, predisposing the
individual to the development of rhabdoid tumors (10, 11).
Despite the commonality of being driven by SMARCB1 or
SMARCA4 loss, there is molecular and clinical heterogeneity
among AT/RT. There are three known DNA methylation
subgroups associated with AT/RT, referred to as TYR
(characterized by the overexpression of melanosomal genes), SHH
(characterized by the overexpression of sonic hedgehog signaling
pathways), and MYC (characterized by the overexpression of both
MYC proto-oncogene and HOX cluster genes) (12–14). AT/RTTYR are diagnosed in the youngest population group (median age
of diagnosis: 12 months) and usually arise in an infratentorial
location (75%). AT/RT-SHH are predominantly supratentorial in
location (65%) and are diagnosed in individuals with a median age
of 20 months. AT/RT-MYC arise in the supratentorial region
(50%), the infratentorial region (38%), and even extracranially in
the spinal cord (12%) and represent the oldest population group
within AT/RT diagnoses at a median age of 27 months. Extracranial
rhabdoid tumors most often show a similarity with the AT/RTMYC subgroup at the DNA methylation level (15, 16). The
commonalities and overlap between subgroups of AT/RT and
subgroups of extracranial RT (speciﬁcally, RTK) are not well
characterized, particularly in patients who present with both types
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METHODS
Human Subjects
Written informed consent was obtained for all participants in
this study under a research protocol approved by the
Institutional Review Board at Nationwide Children’s Hospital
(IRB17-00206). We enrolled three individuals with a diagnosis of
rhabdoid tumor. Our report includes three females: “patient 1”,
“patient 2”, and “patient 3” diagnosed at age 10, 2, and 2 months,
respectively. Two patients presented with multifocal
synchronous AT/RT and RTK primary tumors, one of whom
eventually had metastasis to the lungs. The third patient had a
primary RTK and ultimately experienced tumor metastasis to the
abdomen after an initial surgical resection. Snap-frozen diseaseinvolved tissue was studied, when possible, but for some
specimens only formalin-ﬁxed, parafﬁn-embedded (FFPE)
disease-involved tissue was available for study. A detailed
description of the clinical history of each patient can be found
in the supplementary ﬁle (Case Descriptions).

Samples and Extractions
Normal comparator tissue was obtained from blood-derived
peripheral blood mononuclear cells or from non-tumor kidney
tissue in one individual. The tumor samples were obtained as
either fresh-frozen or FFPE tissue and were used for the coextraction of DNA (AllPrep DNA kit, Qiagen) and RNA
(mirVana isolation kit, Thermo Fisher Scientiﬁc for frozen and
High Pure isolation kit, Roche Life Science for FFPE tissues).
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USA) and, if applicable, treated using the Illumina FFPE restoration
process (catalog number WG-321-1002, Illumina, San Diego, CA,
USA). Bisulﬁte-converted DNAs, including methylated human
DNA controls (catalog number D5014, Zymo Research, Irving,
CA, USA), were hybridized to the Inﬁnium Methylation EPIC
BeadChip (catalog number WG-317-1001, Illumina, San Diego,
CA, USA) following the Illumina Inﬁnium HD Methylation
protocol. Beadchips were imaged on the Illumina iScan System,
and the resulting raw IDAT ﬁles were processed through a local
installation of the German Cancer Research Center (DKFZ) DNA
Methylation Brain Tumor Classiﬁer, version 11b4 or 11b6 (22, 23).
Uniform manifold approximation and projection (UMAP) plots
were generated to assess the unsupervised clustering of the studied
AT/RT samples, where only the most differentially methylated
probes were considered. For comparison of our study samples
with external DKFZ embryonal tumor samples (i.e., AT/RT,
medulloblastomas, and embryonal tumors with multilayered
rosettes), standard deviation ≥0.25 was used, which included
30,549 most differentially methylated probes for clustering analyses.

Exome Sequencing and Analysis
Sequencing libraries were prepared for exome sequencing using
NEBNext Ultra II FS DNA library prep kit (New England
BioLabs). First, target enrichment by hybrid capture was
performed by combining xGen Exome Research Panel with the
xGenCNV Backbone and Cancer-Enriched Panels-Tech Access
(Integrated DNA Technologies). The xGen exome panel (catalog
number 10005153) targets 19,433 genes with a total probe
coverage encompassing 39 Mb of genomic space, while the
xGenCNV backbone panel (catalog number 1080569) consists
of 9,115 individually synthesized probes combined with an
additional 1,855 probes enriching cancer-associated gene
regions. Libraries were then generated using the NEBNext
Ultra II FS kit, and paired-end 151-bp reads were generated on
NovaSeq6000. Alignment to human reference genome build
GRCh38 and secondary analysis were performed using our
previously published pipeline (17).
Germline variants were called using GATK’s HaplotypeCaller.
The variants were then ﬁltered based on the following
characteristics: gnomAD population frequency <0.0001, depth of
sequencing ≥8 reads, variant within protein-coding region or
within 3 base pairs of canonical splice site, and presence of the
gene within a previously published cancer predisposition list of
565 genes (18). VarScan2 and GATK were used to assess copy
number variants (CNVs) and to detect loss of heterozygosity
across all chromosomes (19). Copy number variation plots were
generated from Varscan2-called segment ﬁles and plotted by
centering around a zero-point determined by the median log-2
value of the segments of the ﬁrst ﬁve chromosomes. Invariant copy
data based on log-2 ratios were plotted as 100-bp windows in blue,
wherein copy number variant segments were plotted as a red line
by corresponding log-2 copy ratio and position. Loss of
heterozygosity (LOH) data were plotted for tumor samples
using the position (X axis) and variant allele frequency (VAF; Y
axis) of called alleles ﬁltered by a list of known biallelic sites. Points
falling outside of an expected normal range of 25 to 75% were
marked as LOH-supporting.
Somatic variants were called using MuTect2 (20). Somatic
nonsynonymous SNVs and small insertions or deletions (indels)
were ﬁltered for quality (site quality ≥100), population frequency
(gnomAD population frequency <0.0001), absence in the
germline comparator sample, somatic alternate allele read
depth (≥4 reads), minimum tumor VAF ≥5%, and gene
location within a coding or splice site (≤3 base pairs) region.
Variants passing all the aforementioned ﬁlters were manually
reviewed in Integrated Genomics Viewer and then analyzed for
the presence of the variant within a previously deﬁned cancer
hotspot (21) or the presence of the gene within a previously
published cancer predisposition list of 565 genes (18). VarScan2
and GATK were used to assess CNVs and loss of heterozygosity
across all chromosomes (19). Copy number variation and LOH
data plots were generated as described for germline CNVs.

RNA Sequencing and Gene Expression
Analysis
Tumor RNA was subjected to DNase treatment and
ribodepletion prior to library construction using NEBNext
Ultra II Directional RNA library prep kit for Illumina (New
England BioLabs). Paired-end 151-bp reads were generated on
Illumina HiSeq 4000 and aligned to the human genome reference
sequence build GRCh38. Alignment was performed using a
custom in-house pipeline and the splice-aware aligner STAR
(24). Clustering was performed by principal component analysis
(PCA) on log10(x + 1) and quantile-normalized DESeq2
expression values using a panel of 36 genes with known
relevance to AT/RT subtyping for MYC (HOTAIR, HOXC4/5/
6/8/9/10/11/12/13/AS1/AS5, and MYC), SHH (ASCL1, BOC,
CDH6, DLL1/3, DTX1, GLI2, HES1/5/6, MYCN, and PTCH1),
and TYR (BMP4, DCT, DNAH11, FGFR2, JAK1, MITF, OTX2,
PDGFRB, SPEF1, TYR, and VEGFA) groups (13).

Clonality Analysis
We used superFreq with default parameters to determine
clonality (25). superFreq uses exome BAM ﬁles from tumor
samples and identiﬁes tumor-speciﬁc single-nucleotide variants,
indels, and copy number variants to track clones across multiple
samples from the same patient.

RESULTS
Tissue Pathology
The pathology review typically estimated a high tumor
cellularity/content (average, 95%; range, 90–100%) and a wide
range of necrosis (average, 12%; range, 0–40%) for all tumors
studied (Table 1). As described in the clinical summaries
(Supplementary File- Case Descriptions), the histologic
ﬁndings in all tumors were determined by board-certiﬁed

DNA Array-Based Methylation Proﬁling
For each tumor studied, 250–500 ng of input DNA was bisulﬁteconverted (catalog number D5006, Zymo Research, Irvine, CA,
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pathologists and were consistent with either AT/RT or
extracranial RT supported by loss of INI1 staining.

DNA Methylation Proﬁling and Gene
Expression Clustering and CNV Analysis
Reveal Heterogeneity Between Tumors
From the Same Patient

Genomic Analysis

We generated DNA methylation proﬁles using Illumina EPIC
850K microarray for our cohort of tumors and analyzed the data
using the DKFZ brain tumor methylation classiﬁer v11b4 or
v11b6, which provides the classiﬁcation of 184 known central
nervous system tumors (22). All tumors, including intra- and
extracranial tumors, matched most closely with the methylation
family of AT/RT, and all had conﬁdence scores >0.90 (range:
0.9421–0.9997; Table 1). The brain tumor methylation classiﬁer
also assigns samples to different methylation subgroups or classes
within the AT/RT family. In our cohort, one brain sample was
predicted to be a TYR subgroup and one was predicted to be a
SHH subgroup, while the other ﬁve samples (all non-CNS) were
predicted to be MYC subgroups. Synchronous tumors from the
same patient (patients 1 and 2) demonstrated epigenetic
heterogeneity and were assigned different methylation
subgroups, as visualized by the appearance in distinct UMAP
clusters alongside other embryonal tumors from the DKFZ
database (Supplementary Figure S2). The primary RTK and
abdominal metastatic tumors from patient 3 were both classiﬁed
as MYC and clustered together.
We also performed RNA-seq on all tumors, yielding
>80,000,000 total reads for each RNA sample (Supplementary
Table S1). To explore the heterogeneity of gene expression
between the subgroups of RTs, we performed PCA of the
RNA-seq data using 36 genes (see “Methods”) known to be
divergently expressed in speciﬁc AT/RT subgroups, which
include TYR/MITF/others for TYR subgroup, NOTCH
signaling genes (e.g., ASCL1, HES5/6, and DLL1/3) and SHH
signaling genes (e.g., MYCN and GLI2) for SHH subgroup, and
MYC/HOTAIR/HOXC cluster genes for MYC subgroup (13).
Similar to our methylation clustering, synchronous brain and
extracranial tumors from the same patient demonstrated a
variation in expression proﬁles and appeared in distinct
clusters (Supplementary Figure S3). The resultant gene

The average exome sequencing coverage depth for the tumor
samples was 241X (range: 181X–289X) and for the germline
comparator samples was 216X (range: 186X–266X). For all
samples, an average of 97.9% of coding bases was covered by
at least 20 reads (range, 97.0–98.6%) (Supplementary Table S1).

Germline Analysis
All three patients had a pathogenic germline alteration
affecting SMARCB1 identiﬁed by exome sequencing (Table 1).
Patient 1 had a heterozygous frameshift variant in SMARCB1
(p.Pro215Leufs*14), while patients 2 and 3 had a large deletion
(>1 Mb) of chr22q11, a region which includes the SMARCB1
gene, present in germline comparator tissue, thus conﬁrming a
diagnosis of rhabdoid tumor predisposition syndrome for
all three.

Somatic Analysis
We observed a second somatic hit in SMARCB1 in all tumor
specimens via LOH of chr22, inclusive of the SMARCB1 gene
region. In patient 1, although heterozygous in the germline (48%
VAF), the p.Pro215Leufs*14 variant exhibited much higher allele
frequencies in all three tumor specimens (87% in primary brain,
68% in primary kidney, and 82% in lung metastasis) because of
extensive copy-neutral LOH across chromosome 22q in all three
tumor specimens (Supplementary Figures S1A–C). In patient 2,
the chr22 deletion appeared homozygous in the patient’s
primary brain and primary kidney tumors due to copy-neutral
LOH across the entirety of chromosome 22 (Supplementary
Figures S1D, E). We made similar observations in patient 3, who
harbored a slightly smaller germline deletion on chr22 (1.34 Mb)
that appeared homozygous in both primary kidney and
metastatic abdominal tumors due to copy-neutral LOH
affecting the entire chromosome (Supplementary Figures
S1F, G).

TABLE 1 | Summary of molecular ﬁndings.
ID

Comparatortissue GermlineSMARCB1

Patient
1

Blood

p.Pro215Leufs*14

Patient
2

Kidney,
non-tumor

1.88 Mb deletion
at 22q11.22-q11.23

Patient
3

Blood

1.34 Mb deletion
at 22q11.22-q11.23

Tumorsite

Tumorcontent Necrosis

CNS family (methylation
score)

CNS AT/RT class (methylation
score)

Brain

95%

1%

AT/RT (0.9997)a

TYR (0.9997)a

Kidney
Lung (metastatic)
Brain

90%
90%
100%

30%
40%
0%

AT/RT (0.9421)a
AT/RT (0.9998)b
AT/RT (0.9980)a

MYC (0.9078)a
MYC (0.9977)b
SHH (0.9958)a

Kidney
Kidney

98%
100%

5%
0%

AT/RT (0.9971)a
AT/RT (0.9997)a

MYC (0.9967)a
MYC (0.9997)a

Abdomen
(metastatic)

90%

10%

AT/RT (0.9932)b

MYC (0.9823)b

Unless otherwise indicated, all tissue specimens were from a primary tumor. The estimates of tumor content and necrosis are based on a pathology review.
AT/RT, atypical teratoid rhabdoid tumor; MYC, MYC gene subgroup of AT/RT; SHH, sonic hedgehog subgroup of AT/RT; TYR, tyrosinase subgroup of AT/RT.
a
Classiﬁer versions used for the Heidelberg Brain Tumor and Sarcoma Classiﬁers: v11b4 CNS classiﬁer.
b
Classiﬁer versions used for the Heidelberg Brain Tumor and Sarcoma Classiﬁers: v11b6 CNS classiﬁer.
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supporting the probable shared clonal origin of these two
extracranial tumors. Each extracranial sample was found to
possess a uniquely derived subclone, with kidney and lung
samples gaining a number of exclusive SNVs (7 and 12,
respectively). The subclone identiﬁed in the brain sample was
differentiated only by one SNV, an intronic variant in GPKOW
(Supplementary Table S2). No other CNVs besides chr22 or
chr22q LOH were identiﬁed in any of the tumors
(Supplementary Figures S1A–C). Despite the presence of two
independent tumor lineages and as many as ﬁve distinct clones,
no new diagnostic, prognostic, or therapeutically applicable
SNVs or CNVs were found in any clones beyond the
SMARCB1 events.

expression clustering data supported the subgroup classiﬁcation
predicted by methylation analysis for each sample.

Clonal Tracking Using Single-Nucleotide
Variants and Copy Number Variations
Reveals Heterogeneity Between Tumors
From the Same Patient
Patient 1
While all samples possess second-hit somatic events resulting in
the loss of any functional SMARCB1 allele, the brain lesion
demonstrated a whole-chromosome loss of chr22, whereas the
two extracranial samples exhibited LOH of chr22q only.
Clonality analysis differentiated the brain and extracranial
lesions into two distinct tumorigenic origins on the basis of a
number of other variants. Of the 25 SNVs included in clonal
clustering, none was found to be shared between the brain and
extracranial tumors (Figure 1 and Supplementary Table S2).
The kidney and lung tumors were found to be closely related,
with the kidney and lung tumors sharing four SNVs. Like the
patient’s kidney tumor, the lung metastasis was also classiﬁed as
MYC subgroup based on methylation proﬁling, further

Patient 2
Clonality analysis indicated a shared origin for kidney and brain
samples as the most parsimonious clonal history for this case.
However, only a single event—whole-chromosome copy-neutral
LOH of chr22—is shared between the two tumors. While the
kidney lesion was not found to have any SNVs or CNVs beyond
the initial chr22 LOH, the copy number analysis of the brain
tumor revealed several chromosomal aberrations and two
distinct sequentially derived clones (Figure 2). The ﬁrst clone

FIGURE 1 | –3Clonality analysis. River plots showing the composition of
clones in multiple tumor samples plus matched normal blood (germline)
sample. Vertical lines indicate a sample, labeled on the X-axis. Colored circles
indicate the origins of a clone from a single cell, either of the germline (black)
or a preceding clone. Colored outlines show the cellularity of clones (Y-axis) in
each sample. The percentages shown (in white or black text) indicate the
cellularity of a tumor clone in each sample that was identiﬁed, excluding the
cells of any descendant clones. Clone percentages sum up to the total tumor
cellularity of a sample. The samples are arranged to most clearly visualize
clonal descent but do not represent a formal time-series. The copy number
variants, loss-of-heterozygosity events, and single-nucleotide variants
identiﬁed in the tumor samples as well as relevant germline predisposition
variants are listed on the right and colored by which clone they belong to.

Frontiers in Oncology | www.frontiersin.org

FIGURE 2 | River plots show the composition of clones in multiple tumor
samples plus matched normal blood (germline) sample. Vertical lines indicate
a sample, labeled on the X-axis. Colored circles indicate the origins of a clone
from a single cell, either of the germline (black) or a preceding clone. Colored
outlines show the cellularity of clones (Y-axis) in each sample. Percentages
shown (in white or black text) indicate the cellularity of a tumor clone in each
sample that was identiﬁed, excluding the cells of any descendant clones.
Clone percentages sum to the total tumor cellularity of a sample. Samples are
arranged to most clearly visualize clonal descent but do not represent a
formal time-series. Copy number variants (CNVs), loss-of-heterozygosity
events (LOH), and single nucleotide variants (SNVs) identiﬁed in the tumor
samples, as well as relevant germline predisposition variants, are listed on the
right and colored by which clone they belong to.

5

July 2022 | Volume 12 | Article 932337

Miller et al.

Molecular Characterization of Pediatric Rhabdoid Tumors

was found to be informative of prognosis, diagnosis, or
therapeutic potential for rhabdoid tumors.

(red) added three SNVs and nine full-chromosome CNV events
—a single-copy gain of chr2, chr7, chr11, chr15, chr19, and
chr20; balanced two-copy gains of chr8 and chr18; and a copyneutral LOH of chr5 (Figure 2 and Supplementary Figures 1D,
E). The second, further-derived clone (green) added an
additional of two SNVs plus a loss of heterozygosity of chr14.
These observed molecular differences between the brain and
kidney tumors is further supported by their classiﬁcation into
different methylation subgroups (SHH and MYC, respectively),
indicating that the tumors do not share a clonal origin. Aside
from chr22 LOH, none of the SNVs or CNVs unique to the brain
lesion was found to be meaningful in terms of prognosis,
diagnosis, or therapeutic potential for AT/RT (26).

DISCUSSION
We analyzed seven tumor tissue samples from three pediatric
patients diagnosed with rhabdoid tumors of the brain and/or
extracranial sites and aimed to systematically assess each
individual case using a multimodal approach of DNA and
RNA sequencing plus methylation proﬁling. As expected, all
tumors exhibited biallelic inactivation of SMARCB1, including a
germline SMARCB1 alteration in every patient. We also analyzed
tumors using DNA array-based methylation and RNAseq-based
gene expression analyses to characterize tumors based on known
molecular subgroups of AT/RT (12). Our use of the v11b4/b6
brain tumor methylation classiﬁer provided conﬁdent
classiﬁcations for tumors as either MYC, SHH, or TYR AT/RT
subgroups, even for extracranial RTs (22). We conﬁrmed the use
of analyzing gene expression data from RNA-seq as an
orthogonal method for identifying distinct molecular AT/RT
subgroups by evaluating the expression of known subgroupspeciﬁc marker genes (13).
Our integrated analysis of synchronous tumors from the same
patient revealed several interesting ﬁndings. First, RTs originating
in and outside the brain in each case showed molecularly
heterogeneous methylation proﬁling and were classiﬁed as
different subgroups (patient 1 brain = TYR and kidney = MYC;
patient 2 brain = SHH and kidney = MYC). While the ﬁnding of
divergent methylation patterns in synchronous rhabdoid tumors
has been reported before, our integrated analyses using exome

Patient 3
The two samples in this case, of the kidney and abdomen, were
determined to share a single tumorigenic origin on the basis of
shared SNVs in MST1 and LINGO4, in addition to the chr22
LOH event often observed in rhabdoid tumors (Figure 3 and
Supplementary Figures 1F, G). Methylation proﬁling classiﬁed
both as MYC, supporting the abdominal metastases that share
similar epigenetic features to the kidney tumor and therefore
may share a clonal origin. From this shared clonal origin, three
additional distinct subclones have arisen. The one subclone
present in the kidney (red) sample possesses ﬁve additional
SNVs, while the two sequentially derived abdominal subclones
add 49 (green) and 9 (orange) SNVs, respectively. In each
sample, the derived clones have nearly entirely replaced the
ancestral cell population, resulting in the two tumors being
substantially genetically distinct in a large number of highfrequency variants; none of these derived variants, however,

FIGURE 3 | River plots show the composition of clones in multiple tumor samples plus matched normal blood (germline) sample. Vertical lines indicate a sample,
labeled on the X-axis. Colored circles indicate the origins of a clone from a single cell, either of the germline (black) or a preceding clone. Colored outlines show the
cellularity of clones (Y-axis) in each sample. Percentages shown (in white or black text) indicate the cellularity of a tumor clone in each sample that was identiﬁed,
excluding the cells of any descendant clones. Clone percentages sum to the total tumor cellularity of a sample. Samples are arranged to most clearly visualize clonal
descent but do not represent a formal time-series. Copy number variants (CNVs), loss-of-heterozygosity events (LOH), and single nucleotide variants (SNVs)
identiﬁed in the tumor samples, as well as relevant germline predisposition variants, are listed on the right and colored by which clone they belong to.
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sequencing and clonal tracking demonstrated that, aside from
chr22 LOH, the brain and extracranial tumors demonstrated
further molecular heterogeneity and never shared any tumor
SNVs or CNVs (Figures 1, 2) (15, 27). Although the tumors
from patient 2 were initially predicted to share a clonal origin
(using superFreq software), this is likely because of the
commonality of chr22 LOH and the fact that the kidney tumor
did not possess any other CNVs or SNVs. In fact, LOH of chr22 or
chr22q was a ubiquitous event observed in all tumors within our
cohort and is likely the most common mechanism for a second hit
in SMARCB1 in patients with rhabdoid tumor predisposition
syndrome (i.e., germline SMARCB1 mutation). As chr22 LOH is
common in this tumor type, it is most likely that the true
explanation is that an indistinguishable event occurred in two
separate instances for the brain and extracranial RT to have been
formed—for example, in patient 2. This explanation is supported
by the high cellularity of the ﬁrst derived brain clone (red) in
patient 2, suggesting that it may be the true tumorigenic ancestor
of the brain lesion (Figure 2). Due to the lack of any other shared
genomic alterations (besides chr22 LOH) and the lack of a
biological mechanism for metastasis between the kidney and
brain, the more plausible explanation is that the loss of chr22
has occurred twice separately. However, as the events alone are
indistinguishable, a metastatic event is conceivably possible and
cannot be excluded with certainty. In patient 3, we observed the
same methylation proﬁle for both kidney and abdominal lesions,
and additionally we identiﬁed two shared SNVs between the two
tumors at >40% VAF, indicating a likely shared clonal origin
(Supplementary Table S2). While most of the tumors in our
cohort appeared to derive clones, it was composed of either noncoding SNVs (intronic or promoter regions) or other passenger
mutations, primarily nonsynonymous variants in genes not
previously associated with cancer. Interestingly, only one tumor
in our cohort (patient 2 brain) had additional CNVs besides chr22
LOH, highlighting the importance of using exome sequencing to
study the tumors fully.
Given that AT/RT is a heterogenous disease with different
subgroups, the goal is that molecular studies and ﬁndings can be
used to guide therapy and improve patient outcomes. Several
epidemiological studies have independently reported that
patients with AT/RT-TYR or ASCL1-expressing (NOTCH
signaling) ATRT-SHH tumors have a better prognosis, but
more analyses on larger prospective cohorts are needed to
conﬁrm these ﬁndings (12, 28–30). In addition, several
preclinical studies have identiﬁed drugs and drug-like
inhibitors with different therapeutic effects in molecular
subgroups of AT/RTs (31–33). Therefore, it is likely that
molecular subgrouping of rhabdoid tumors is expected to
affect patient management in the future, as there may be
differences in response to different therapies and overall
survival. While our ﬁndings are of biological interest, there
may also be clinical value in using comprehensive molecular
proﬁling to diagnose and classify rhabdoid synchronous tumors,
particularly given the potential prognostic and therapeutic
implications for different rhabdoid tumor subgroups.
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Supplementary Figure 1 | Genome-wide copy number plots. In the top window
of each panel are copy number plots, where blue points represent the log-2 ratio for
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utilizing 36 genes (see “Methods”) known to be differentially expressed in distinct
AT/RT subgroups. The samples are colored by their RT subgroup as called by
methylation proﬁling and as central nervous system (CNS) or non-CNS indicative of
the tumor location.

the tumor relative to the normal specimen and red lines represent copy number
variants segments as called by GATK. The heterozygosity plots (bottom window of
each panel) show the tumor variant allele frequency (VAF) for heterozygous germline
variants, which are colored red if they exhibit signiﬁcant evidence of loss of
heterozygosity (LOH) from the expected 50% VAF. The horizontal blue lines indicate
contiguous LOH segments. Included are patient 1 primary brain tumor (A), primary
kidney tumor (B), and metastatic lung tumor (C); patient 2 primary brain tumor (D),
and primary kidney tumor (E); and patient 3 primary kidney tumor (F) and metastatic
abdominal tumor (G).

Supplementary Table 1 | Exome sequencing metrics. Top: the 10 samples
obtained from individuals are listed along with the type of tissue (tumor or
comparator), sample type, mean depth of target exon coverage, and percent of
targeted bases per gene sequenced to 20× coverage. Bottom: metrics from RNAsequencing. The seven samples upon which RNA-seq was performed are listed
along with tumor type, sample preservation type, total number of reads, number of
reads mapped to GRCh38, and number of coding and untranslated region reads.
The corresponding dbGap ID for each sample is listed. FFPE, formalin-ﬁxed
parafﬁn-embedded; GRCh38, human genome assembly (hg38) from Genome
Reference Consortium; UTR, untranslated region

Supplementary Figure 2 | Unsupervised clustering by uniform manifold
approximation and projection (UMAP) of embryonal tumors indicates the grouping
of rhabdoid tumor (RT) tumors by methylation classiﬁcation. The seven samples
from our study were compared to 545 embryonal tumors [atypical teratoid (AT)/RT,
medulloblastoma, and embryonal tumors with multilayered rosettes] described by
Capper et al. (22) by unsupervised UMAP clustering, using the most differentially
methylated probes (standard deviation ≥0.25, n = 30549 probes). The seven
tumors from our cohort were grouped according to their predicted classiﬁcations,
as assigned by the DKFZ CNS Classiﬁer v11b4/v11b6. The samples from our
cohort are outlined in black and are ﬁlled with color by their AT/RT subgroup as
called by previous methylation proﬁling.

Supplementary Table 2 | Single-nucleotide variants and copy number variants
detected in clonality analysis. Variants detected in clonal tracking are listed with
corresponding variant allele frequencies predicted from exome sequencing data.
The color of the clone corresponding to –5 is also noted.
CASE DESCRIPTIONS | Clinical history of all three patients, which includes
diagnostic details, treatment regimens, and the current clinical status of each
patient.

Supplementary Figure 3 | Clustering by RNA-seq expression recapitulates
subgrouping of rhabdoid tumors. Principal component analysis was performed by
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